Free Trial

Petros Pharmaceuticals Q2 2024 Earnings Report

Petros Pharmaceuticals logo
$0.29 -0.02 (-5.67%)
(As of 12/20/2024 05:31 PM ET)

Petros Pharmaceuticals EPS Results

Actual EPS
-$0.37
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Petros Pharmaceuticals Revenue Results

Actual Revenue
$1.42 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Petros Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

This is the worst sign for the U.S. stock market in 50 years (Ad)

The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

Petros Pharmaceuticals Earnings Headlines

This is the worst sign for the U.S. stock market in 50 years
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)
See More Petros Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Petros Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Petros Pharmaceuticals and other key companies, straight to your email.

About Petros Pharmaceuticals

Petros Pharmaceuticals (NASDAQ:PTPI), a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

View Petros Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings